Vaccine Adjuvant Market

Global Vaccine Adjuvant Market Size (2024 to 2032)

In 2023,the global vaccine adjuvant market was valued at USD 711.3 million and it is expected to reach USD 1713.32 million by 2032 from USD 788.12 million in 2024, growing at a CAGR of 10.8 % during the forecast period. 

Current Scenario of the Global VACCINE ADJUVANT MARKET

The global vaccine adjuvants market comprises veterinary and human adjuvants, which are used to increase the efficiency of vaccines. In addition, vaccine adjuvants are accredited with assisting in boosting the immune response in the host post-vaccination. Immunologists and infectious disease specialists are in covenant over the advantageous uses of adjuvants in vaccines today. Notably, to decrease the number of doses, surge the probability of a continuous immunological response, and reduce the overall prevalence of the disease. In addition, the immune response to vaccine antigens has been improved with the use of adjuvants for decades. They recover the body's immune reaction and frequently allow fewer deactivated viruses or bacteria to be used in a vaccine. However, the final vaccine product may present more than one adjuvant.

MARKET DRIVERS 

The growing demand for vaccines and the emergence of new diseases propel the vaccine adjuvants market growth.

Across the world, the consumption of vaccines is increasing as it is one of the effective ways to be protected from various diseases. Various governments have been conducting numerous programs to promote vaccination among people, and the awareness levels among people regarding the advantages associated with vaccinations have improved in recent days, which is anticipated to result in the growth of the vaccine adjuvants market. In addition, the growing prevalence of infectious diseases and the introduction of new diseases are promoting the market’s growth rate. For instance, the recent COVID-19 pandemic has increased the demand for vaccines and adjuvants to protect against these diseases.

In addition, the growing incidence of infectious and zoonotic diseases, growing focus on vaccination programs by numerous government bodies, and rising focus on enhanced and long-term immunization besides current and emerging diseases are accelerating the growth rate of the global vaccine adjuvant market. Furthermore, growing R&D expenditure and attainments, associations, and agreements by market participants are other notable factors driving the market's growth. Furthermore, advancements in adjuvant formulations, the growing adoption rate of recombinant subunits, and synthetic vaccines boost the global adjuvant market growth. The growing demand for vaccine adjuvants and untouched market potential in developing countries offer numerous growth possibilities to the adjuvant vaccine manufacturers and key players in the market.

MARKET RESTRAINTS

However, side effects associated with the adjuvants and high toxicity adjuvants are the primary restraint to the global vaccine adjuvant market. High costs associated with adjuvant-based research and established protection are restraining market growth. The denying effect of adjuvants' toxicity on the vaccine's manufacturing cost and protective profiles inhibits the growing market demand. The adverse effects of adjuvants and high-toxicity adjuvants are factors impeding the vaccine adjuvant market growth during the forecasting timeline. Moreover, insufficient knowledge among people and inadequate healthcare facilities hampers the growing market rate. Low research activities in its development also hinder the market.

REPORT COVERAGE

SEGMENTAL ANALSIS

Vaccine Adjuvant Market Analysis By Type

Based on type, the carbohydrate adjuvants segment accounted for a significant market share and is anticipated to grow further during the forecast period.

The aluminum salts segment is estimated to grow at a healthy CAGR during the forecast period due to rising innovation and the introduction of particulate adjuvants. Aluminum salts vaccine has been growing continuously in the market for the last two decades due to the safety of cancer patients. Also, new adjuvants have come up with innovative facilities such as the more muscular battle to disease and having a more shelf life than others due to the easier availability of aluminum salts in nature and the high adoption of particulate vaccines.

Vaccine Adjuvant Market Analysis By Route of administration

Based on the administration route, the Intramuscular segment dominates the vaccine adjuvants market because this is the fastest and most highly effective Route. On the other hand, the intradermal route segment is likely to contribute a significant market share as it takes more time for absorption and action. 

Vaccine Adjuvant Market Analysis By Mechanism of Action

Based on the mechanism of action, the immune stimulants segment dominates the adjuvant vaccine market owing to the high demand for adjuvants for stimulating antigens to the immune system.

REGIONAL ANALYSIS

Geographically, the North American vaccine adjuvant market led the market in 2023, and the region's domination is likely to continue throughout the forecast period. The rapidly growing geriatric population and rising government funding around R&D of vaccines across North American countries are propelling the adjuvant vaccine market in the North American region. In addition, the growing innovations, increasing product portfolios of key players, and increasing investments to conduct R&D are further favoring the vaccine adjuvant market in the North American region.

The European vaccine adjuvant market had a substantial share of the global market in 2023 and is estimated to progress considerably during the forecast period owing to an increase in patients affected by diseases like cancer and other infections. Furthermore, favorable reimbursement policies have been notable factors propelling the regional market growth. In addition, Europe is one of the severely impacted regions by the COVID-19 pandemic, which has further improved the scope of the vaccine adjuvants market in this region.

On the other hand, the Asia Pacific vaccine adjuvant market is anticipated to display a consistent CAGR and is expected to maintain the trend due to the increasing population and diseases like HIV, hepatitis, cancer, influenza, and others. The population in APAC is growing significantly. Countries such as India and China are largely populated countries worldwide. The growing population from the APAC countries is anticipated to demand greater production of vaccines, which is anticipated to have a favorable impact on the regional market growth. The Indian market is expected to grow at a notable CAGR during the forecast period owing to the growing number of awareness campaigns by the Indian government. For instance, the Universal Immunization Program (UIP) is one of the major vaccination programs in India. It provides vaccines for diphtheria, pertussis, tetanus, polio, hepatitis B, measles, mumps, rubella, and Haemophilus influenzae type b (Hib).

The Latin America vaccine adjuvant market is anticipated to showcase a healthy CAGR in the coming years. The growing awareness among the Latin American population regarding the vaccination benefits and increasing incidence of infectious diseases such as influenza and pneumonia propel the regional market growth.

The vaccine adjuvant market in MEA is predicted to occupy a moderate share and grow at a sluggish CAGR during the forecast period.

KEY PLAYERS IN THE VACCINE ADJUVANT MARKET

Some of the promising companies operating in the global vaccine adjuvants market include MPV Technologies (U.S.), Avanti Polar Lipids, Novavax Inc. (U.S.), Brenntag Biosector (Denmark), SEPPIC (France), Agenus, Inc. (U.S.), Invivogen (U.S.), SPI Pharma, Inc. (U.S.), CSL Limited (Australia), and OZ Biosciences (France).

RECENT MARKET DEVELOPMENTS

• In 2020, The U.S. food and drug administration approved Seqirus for its new product AUNDEZ to treat Influenza prevention. It is the first monovalent vaccine adjuvant to protect against influenza A H5N1 in the pandemic.

• In 2020, GSK announced it would come into the market with innovative doses of vaccine adjuvant to enhance the COVID-19 outbreak. GSK has invested a lot in developing 1 billion doses of adjuvanted vaccine next year.

• In 2018, Croda acquired the Brenntag bio sector to develop an adjuvant vaccine for serving humans and the veterinary market.

DETAILED SEGMENTATION OF THE GLOBAL VACCINE ADJUVANT MARKET  INCLUDED IN THIS REPORT

This market research report on the global vaccine adjuvant market has been segmented based on the type, Route of administration, mechanism of action, and region.

By Type

• Aluminum Salts
• Tensoactive Adjuvants
• Adjuvant Emulsions
• Bacteria Derived Adjuvants
• Liposome Adjuvants
• Carbohydrate Adjuvants

By Route of administration

• Oral
• Intradermal
• Subcutaneous
• Intranasal
• Intramuscular

By Mechanism of Action

• Immune Stimulants
• Carriers
• Vehicle Adjuvants

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa